New Perspectives in Tolerance Induction for Vascularized Composite Allograft transplantation

Jeng-Yee Lin and Shuen-Kuei Liao

1Division of Plastic Surgery, Department of Surgery, Taipei Medical University Hospital, and Medical College, Taipei Medical University, Taipei, Taiwan
2Graduate Institute of Cancer Biology and Drug Discovery and Center of Excellence for Cancer Research, Taipei Medical University, Taipei, Taiwan

Corresponding author: Shuen-Kuei Liao, Taipei Medical University, 250 Wu-Hsing St., Taipei 11031, Taiwan, Tel: +886-0912-753-715; E-mail: liaosk@h.tmu.edu.tw

Abstract

Although transplantation of Vascularized Composite Allografts (VCA) has become a clinical reality, complications resulting from long-term immunosuppression remain major barriers to broader indication. Ideally, induction of tolerance has been considered the Holy Grail in both solid organ and VCA transplantation. Recent advances in immunomodulatory medication and cell-based therapy exploiting donor bone marrow (BM) cells, regulatory T cells (Tregs) and mesenchymal stem cells have opened exciting opportunities for tolerance induction in VCA transplantation. This mini-review focuses on current understanding of these drugs and cell-based immunomodulatory strategies and their role(s) in tolerance induction for VCA transplantation.

Keywords: Tolerance induction; Vascularized composite; Allograft; transplantation, Regulatory T Cell; Mixed chimerism

Introduction

To date, clinical transplantations of a variety of vascularized composite allografts (VCA) including 23 faces, close to 85 upper extremities along with abdominal wall [1], total larynx [2], bone and joint [3], and tongue [4] have been performed in the past two decades with remarkable outcomes regarding graft survival and graft function. Immunosuppressive medication is widely used in current clinical practice to ensure immediate post-transplantation allograft function and survival. However, complications from long-term immunosuppression such as infection, malignancy, or metabolism disorders have made a wider clinical application of VCA transplantation not justifiable since VCA transplantation itself is not life-saving. In addition, acute rejection episodes and chronic graft rejection leading to graft loss have not been totally avoided with current immunosuppressive drugs. Therefore, tolerance induction would be an ideal solution to current problems facing solid organ or VCA transplantation. Two kinds of mechanism are responsible for maintaining tolerance in humans, namely, (i) the central tolerance which involves clonal deletion of allo-reactive lymphocytes in the thymus and (ii) the peripheral tolerance that takes place outside thymus leads to continued inhibition, anergy or deletion of allo-reactive lymphocytes by regulatory T lymphocytes (Treg) [5]. A variety of protocols for tolerance induction are currently under extensive investigation. The protocols that mainly involve central tolerance mandate a certain degree of myeloablative irradiation in the host to allow engraftment of donor Bone Marrow (BM) cells after transplantation, which in turn induces tolerance to subsequent allotransplantation and creates co-existence of both donor and host blood cells (hematopoietic chimerism). Creation of stable chimerism, though reliable in tolerance induction, can hardly be used routinely within clinical setting due to the requirement of host irradiation and the risk of Graft-Versus-Host Disease (GVHD). Therefore, paradigm shift occurred in methods of tolerance induction that depend more upon immunomodulation from Tregs. Recently developed immunomodulatory drugs, cell-based therapy, or both in combination have engaged a more important role from Tregs and have provided a new hope for tolerance induction in clinical VCA transplantation.

Immunosuppressive Drugs

The current immunosuppression protocols in clinical VCA transplantation are extrapolated from regimens used in solid organ transplantation [6], commencing with induction therapy with polyclonal antithymocyte globulins, or monoclonal antibody (mAb) (alemtuzumab, basiliximab), followed by triple-drug maintenance therapy (tacrolimus, mycophenolate mofetil, and steroid). Maintenance may be interspersed with rescue therapies if episodes of acute rejection occur. However, the experimental evidence suggests that these immunosuppressants do not induce tolerance by themselves [7,8]. Therefore, newer drugs have been developed to promote tolerogenic effect and reduce immunosuppressive dosage. Intriguingly, rapamycin and everolimus selectively facilitate expansion of human Tregs and preserve the immunosuppressive activity of Tregs in vitro, which in turn suppress donor reactive cells [9]. Mycophenolate mofetil when combined with 1α, 25–dihydroxyvitamin D3 has been shown to increase Treg frequency and induce transplantation tolerance in a mouse experimental model [10]. A short-term (14-days) course of cyclosporine, a calcineurin inhibitor, in conjunction with IL-2/Fc fusion protein promotes tolerance by allowing exaggerated activation-induced cell death of effector T cells and at the same time enhancing allospecific immunoregulatory function of Tregs in a rodent experiment [11]. Additionally, manipulation of one or more of co-stimulation signals on T cells through CD154, CD28 and inducible T cell co-stimulator (ICOS) has a great potential in tolerance induction for VCA transplantation (Table 1).
Costulatory blockade could lead to T cell inhibition, anergy, or deletion despite the successful interaction of T cell receptor with processed peptide-MHC complex, a step being a prerequisite for T cell activation. Abatacept and Belatacept (human CTLA4-Ig fusion protein) are two clinically approved drugs for prophylaxis of renal transplant rejection. They inhibit T cell response by competing with CD28, a costimulatory molecule, thereby decreasing IL-2 secretion and promoting expansion of Tregs. Other therapeutic strategies of costimulatory blockade under intensive investigations include anti-CD28, anti-CD154, and anti-CD40 antibodies. These newly developed biological drugs hold promises in clinical VCA transplantation.

**Cell-based Therapy**

Mixed hematopoietic chimerism has been reliable for tolerance induction and long-term allograft survival [12-14]. However, this approach is limited in its clinical feasibility due to the requirement of host conditioning and the risk of GVHD. Clinically, a cell-based therapy using donor BM cell transfusion has been reported to minimize the maintenance of immunosuppression in both organ and upper extremity transplantations probably through a mechanism involving chimerism [15]. The approach with BM infusion either to induce hematopoietic chimerism or for the intensification of clonal deletion despite the successful interaction of T cell receptor with processed peptide-MHC complex, a step being a prerequisite for T cell activation. Abatacept and Belatacept (human CTLA4-Ig fusion protein) are two clinically approved drugs for prophylaxis of renal transplant rejection. They inhibit T cell response by competing with CD28, a costimulatory molecule, thereby decreasing IL-2 secretion and promoting expansion of Tregs. Other therapeutic strategies of costimulatory blockade under intensive investigations include anti-CD28, anti-CD154, and anti-CD40 antibodies. These newly developed biological drugs hold promises in clinical VCA transplantation.

**Cell-based Therapy**

Mixed hematopoietic chimerism has been reliable for tolerance induction and long-term allograft survival [12-14]. However, this approach is limited in its clinical feasibility due to the requirement of host conditioning and the risk of GVHD. Clinically, a cell-based therapy using donor BM cell transfusion has been reported to minimize the maintenance of immunosuppression in both organ and upper extremity transplantations probably through a mechanism involving chimerism [15]. The approach with BM infusion either to induce hematopoietic chimerism or for the intensification of clonal deletion of allo-reactive effector T cells and regulation upon immunoregulation from Tregs to maintain allograft survival, it seems to lower the threshold for effective Treg function [24]. Thus, tools that can effectively expand allo-specific Tregs are currently under extensive exploration [25-27]. One of the most actively investigated approaches is donor specific transfusion (DST) and anti-CD154 mAb treatment [12,28-30]. Although deletional mechanism is not complete in regimens involving DST plus costimulatory blockade (e.g. anti-CD154 mAb), which still rely largely upon immunoregulation from Tregs to maintain allograft survival, it seems to lower the threshold for effective Treg function [24]. Other potential cell-based therapies (Table 1) currently under extensive investigation include tolerogenic dendritic cells and adipose-derived mesenchymal stem cells [31-33]. Dendritic cells are antigen presenting cells, the majority of which are functionally immature and incapable of presenting donor antigen to T cells efficiently, therefore leading to disabled T cell activation [34]. Mesenchymal stem cells of the recipient origin could provide the convenience, elicit immense tolerogenic effects and ameliorate GVHD after hematopoietic stem cell transplantation [35,36]. In addition, mesenchymal stem cells promote neurogenesis and facilitate recovery of VCA (as in hand transplant) function following transplantation. Therefore, fine-tuning of the tolerance induction protocol using recipients’ mesenchymal stem cells

### Table 1: Therapeutic strategies for tolerance induction in VCA transplantation

<table>
<thead>
<tr>
<th>Immunomodulatory drug</th>
<th>Protocol characteristics</th>
<th>Disadvantages, side effects or other remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapamycin/everolimus</td>
<td>Immunosuppression, Treg expansion, clinically approved</td>
<td>Leukocytopenia, anemia, skin rash</td>
</tr>
<tr>
<td>MMF+Vitamin D3</td>
<td>Immunosuppression, Treg expansion, clinically approved</td>
<td>Leukocytopenia, anemia, skin rash</td>
</tr>
<tr>
<td>Abatacept/Belatacept</td>
<td>CTLA4-Ig fusion protein, inhibition of T cell activation and increase Treg; clinically approved</td>
<td>Post-transplantation, lymphoproliferative disorder</td>
</tr>
<tr>
<td>Anti-CD154</td>
<td>Blockade of CD154/CD40 costimulation, increase Treg,</td>
<td>Thromboembolism</td>
</tr>
<tr>
<td>Anti-CD28</td>
<td>Blockade of CD28/CD80CD86 costimulation; increase Teg; animal studies</td>
<td></td>
</tr>
<tr>
<td>Anti-CD40</td>
<td>Blockade of CD154/CD40 costimulation, increase Treg, animal studies</td>
<td></td>
</tr>
<tr>
<td>Cell-based therapy</td>
<td>Protocol characteristics</td>
<td>Disadvantages, side effects or other remarks</td>
</tr>
<tr>
<td>Mixed hematopoietic chimerism</td>
<td>Induction of reliable tolerance, application only in selected clinical cases where BMT is needed.</td>
<td>Host conditioning with myeloablation is required for stable chimerism; risk of GVHD.</td>
</tr>
<tr>
<td>BM transfusion</td>
<td>Reduction of immnosuppression, animal studies and preclinical trials</td>
<td>Unable to induce tolerance in humans</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td>Prolongation of allograft survival, animal studies</td>
<td>Unable to induce tolerance in humans</td>
</tr>
<tr>
<td>Treg</td>
<td>Induction of tolerance to VCA in animal models</td>
<td>Unable to induce tolerance in humans</td>
</tr>
<tr>
<td>Mesenchymal stem cells</td>
<td>Induction of tolerance in animal models</td>
<td></td>
</tr>
</tbody>
</table>
for its optimization potentially could be an appealing approach in tolerance induction for VCA transplantation.

**Discussion**

Interestingly, VCA transplantation has been found to have less immunogenicity than transplantation of each component itself, especially the skin component which in the past is considered the most immunogenic one. One possible explanation is the unique feature of VCA such as arm or bone and joint that may naturally involve vascularized transplantation of BM cells along with VCA transplantation, and therefore provide a constant source of donor BM cells to facilitate tolerance induction through a mechanism not yet fully understood. The mechanism involved may have been associated with macro-, mixed or micro-chimerism. In fact, use of maintenance immunosuppression in hand transplantation has resulted in 100% patients and graft survival in 1 year post transplantation, an outcome that has not been able to achieve in any other field of transplantation [37].

The clinical use of CLTA4-Ig (Abatacept and Belatacept) is associated with post-transplantational lymphoproliferative disorder and failure to prevent rejection. Also, clinical trial of anti-CD154 mAb developed thromboembolic complications due to activated platelet expressing CD154 [38]. Therefore, development of new costimulation blockade drugs that prove safe and more efficacious is warranted.

A growing body of evidence has shown that use of costimulation blockade or Treg leads to tolerance induction and long term allograft acceptance in rodent models. However, no evidence has been shown so far that these new immunomodulatory drugs or Tregs themselves, when used alone, can induce tolerance in humans. These differences may partially be accounted for the increased complexity of higher vertebral immune system and the increased diversity of preexisting immunity due to exposure of environmental antigens [38,39].

These data present the rationale for combination therapy using both deletional and regulatory mechanisms for tolerance induction while reducing immunosuppression regimen after VCA transplantation. Nevertheless, combination of such a concept with high-dose multi-drug immunosuppression might be counterproductive because regulatory mechanisms require persistence of a certain degree of immune response to be successful in a clinical setting [40-42].

In conclusion, continued research on and implementation of novel immunomodulatory drugs together with these cell-based therapies can further help to reduce immunosuppression, induce immune tolerance, and optimize outcome of clinical VCA transplantation.

**Acknowledgements**

This work was supported in part by grants from Taipei Medical University Hospital (100-TMU-TMUH-11) and the Department of Health of Taiwan (DOH99-TD-111-008).

**References**


